Community register of orphan medicinal products

Target entity: Community register of orphan medicinal products
Context triple: [Regulation (EC) No 141/2000 on orphan medicinal products, establishes, Community register of orphan medicinal products]

• A. Regulation (EC) No 141/2000 on orphan medicinal products
  Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
• B. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• C. Committee for Orphan Medicinal Products
  The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
• D. WHO Collaborating Centre for Drug Statistics Methodology
  The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
• E. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Community register of orphan medicinal products
Target entity description: The Community register of orphan medicinal products is the official European Union list of medicines designated for the diagnosis, prevention, or treatment of rare diseases, maintained under the EU’s orphan drug framework.

• A. Regulation (EC) No 141/2000 on orphan medicinal products
  Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
• B. Conditional Marketing Authorization by European Medicines Agency
  Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
• C. Committee for Orphan Medicinal Products
  The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
• D. WHO Collaborating Centre for Drug Statistics Methodology
  The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
• E. Certificates of Suitability to the monographs of the European Pharmacopoeia
  Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
• F. None of above. chosen